Skip to main
VTVT

vTv Therapeutics (VTVT) Stock Forecast & Price Target

vTv Therapeutics (VTVT) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

vTv Therapeutics is a biotech company with a promising lead candidate, cadisegliatin, which has received Breakthrough Therapy Designation and is currently in Phase 3 trials for the treatment of Type 1 Diabetes. The drug has shown potential in reducing hypoglycemia and A1C levels, and has a safe dosage of 800mg. The company has a strong financial outlook and is led by a CEO with experience in the pharmaceutical and medical device industry. However, they face risks related to intellectual property, competition, and financing.

Bears say

vTv Therapeutics is a late-stage biopharmaceutical company with a focus on developing treatments for diabetes and other chronic diseases. However, the negative outlook is primarily driven by a lack of confidence in the company's main drug candidate, cadisegliatin, and its ability to receive FDA approval. While management remains optimistic and has made strategic partnerships, the company's financials and lack of pipeline diversity may limit its potential for success.

vTv Therapeutics (VTVT) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of vTv Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About vTv Therapeutics (VTVT) Forecast

Analysts have given vTv Therapeutics (VTVT) a Strong Buy based on their latest research and market trends.

According to 5 analysts, vTv Therapeutics (VTVT) has a Strong Buy consensus rating as of Jul 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

vTv Therapeutics (VTVT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.